文献速递肝病

泼尼松(龙)剂量与自身免疫性肝炎患者缓解机会

Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-01-06

多中心回顾性队列研究纳入451例自身免疫性肝炎成人患者,比较初始泼尼松(龙)高剂量(≥0.50 mg/kg/天,n=281)与低剂量(<0.50 mg/kg/天,n=170)诱导治疗6个月时的转氨酶正常率,两组无显著差异(70.5% vs 64.7%,P=.20),校正混杂因素后也无差异(OR 1.21,95%CI 0.78-1.87,P=.38);高剂量组6个月内累积泼尼松(龙)用量更高(中位3780 mg vs 2573 mg,P<.01)。

要点

  • 高剂量与低剂量泼尼松(龙)诱导组的6个月转氨酶正常率无显著差异(70.5% vs 64.7%,P=.20)。
  • 多变量校正后两组转氨酶正常可能性仍无差异(OR 1.21,95%CI 0.78-1.87,P=.38)。
  • 初始高剂量组6个月内泼尼松(龙)累积用量更高(中位3780 mg vs 2573 mg,P<.01)。

核心结论

  • 在欧洲自身免疫性肝炎患者回顾性研究中,诱导缓解的泼尼松(龙)剂量相关性低于既往假设。
  • 初始泼尼松(龙)剂量低于0.50 mg/kg/天可大幅减少不必要的泼尼松(龙)暴露。

研究设计与样本

  • 多中心回顾性队列研究,采用比较效果设计,纳入1978年至2017年在5个欧洲国家9个中心开始治疗的451例成人自身免疫性肝炎患者。
  • 患者分为高剂量组(初始泼尼松(龙)剂量≥0.50 mg/kg/天,n=281)或低剂量组(<0.50 mg/kg/天,n=170),采用逻辑回归比较结局。

主要发现

  • 高剂量组与低剂量组6个月转氨酶正常率无显著差异(70.5% vs 64.7%,P=.20)。
  • 多变量逻辑回归校正混杂因素后,两组转氨酶正常可能性无差异(OR 1.21,95%CI 0.78-1.87,P=.38)。
  • 初始高剂量组6个月内泼尼松(龙)中位累积剂量高于低剂量组(3780 mg vs 2573 mg,P<.01)。

关键数值与推荐

  • 欧洲肝脏研究学会临床实践指南建议泼尼松(龙)剂量范围为0.50-1 mg/kg/天。
  • 主要结局为开始治疗6个月后血清转氨酶水平正常。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with autoimmune hepatitis (AIH) commonly receive induction therapy with predniso(lo)ne followed by maintenance therapy with azathioprine. European Association for Study of the Liver clinical practice guidelines advise a predniso(lo)ne dose range of 0.50-1 mg/kg/day, which leaves room for practice variation. We performed a multicenter study to determine the efficacy of different dose ranges of predniso(lo)ne induction therapy in a large European cohort of patients with AIH. METHODS: We performed a retrospective cohort study using a comparative effectiveness design. We collected data from 451 adults with AIH who began treatment from 1978 through 2017 at 9 centers in 5 European countries. We assigned patients to a high-dose group (initial predniso(lo)ne dose ≥0.50 mg/kg/day; n = 281) or a low-dose group (<0.50 mg/kg/day; n = 170). Logistic regression was performed to determine difference in outcomes between the groups. The primary outcome was normal serum levels of transaminases at 6 months after initiation of therapy. RESULTS: There was no significant difference in rates of normalization of transaminases between the high-dose predniso(lo)ne group and the low-dose group (70.5% vs 64.7%; P = .20). After multivariable logistic regression with correction for confounders, there was no difference in the likelihood of normalization of transaminases between the groups (odds ratio, 1.21; 95% CI, 0.78-1.87; P = .38). Patients given an initial high dose of predniso(lo)ne received more predniso(lo)ne over time than patients started on a lower dose (median doses over 6 months: 3780 mg vs 2573 mg) (P < .01). CONCLUSIONS: In a retrospective study of patients with AIH in Europe, we found that the dose of predniso(lo)ne to induce remission in patients with AIH is less relevant than assumed. An initial predniso(lo)ne dose below 0.50 mg/kg/day substantially decreases unnecessary exposure to predniso(lo)ne in patients with AIH.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pape S, Gevers TJG, Belias M, et al. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2019. PMID: 30625402. doi:10.1016/j.cgh.2018.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。